Teplizumab to delay type 1 diabetes onset

The primary findings of this TrialNet-based study of teplizumab showed that a 14-day course of the anti-CD3 monoclonal antibody significantly delayed onset of type 1 diabetes in high-risk people with two or more autoantibodies.

The researchers hope to report new mechanistic and metabolic data at the 55th EASD Annual Meeting (EASD 2019):

Results from the Anti-CD3 mAb (teplizumab) prevention trial
Tuesday, September 17, 13:15–14:15. Vilanova Hall, Fira Barcelona Gran Via, Spain 
Session Chair: L. Chatenoud, France

1. Clinical data, background, results, features of the participants associated with clinical responses; conclusions and significance. K. C. Herold, USA
2. Studies of the mechanism of teplizumab. P. S. Linsley, USA
3. Commentary. A. G Ziegler, Germany 

What our Editorial Board said:

A potentially interesting look at long-term data from trials of this potential immunotherapy for type 1 diabetes.

– John Wilding, Professor of Medicine, UK